Randomised clinical trial: Rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 8, 2011, Pages 853-861

  Sanyal, A ^a   Younossi, Z M ^b   Bass, N M ^c   Mullen, K D ^d   Poordad, F ^e   Brown, R S ^f   Vemuru, R P ^g   Mazen Jamal, M ^h   Huang, S ⁱ   Merchant, K ⁱ   Bortey, E ⁱ   Forbes, W P ⁱ  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g Permian Gastroenterology Associates   (United States)

^h VA LONG BEACH HEALTHCARE SYSTEM   (United States)

ⁱ Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTULOSE; PLACEBO; RIFAXIMIN;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CHRONIC LIVER DISEASE QUESTIONNAIRE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CANADA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LINEAR MODELS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RIFAMYCINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 80053214571     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04808.x     Document Type: Article

References (42)

1. Kim WR, Brown RS Jr, Terrault NA, El-Serag H,. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-42. (Pubitemid 34700782)
2. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128-38. (Pubitemid 44337640)
3. Bolden L, Wicks MN,. Predictors of mental health, subjective burden, and rewards in family caregivers of patients with chronic liver disease. Arch Psychiatr Nurs 2010; 24: 89-103.
4. Miyazaki ET, Dos SR Jr, Miyazaki MC, et al. Patients on the waiting list for liver transplantation: caregiver burden and stress. Liver Transpl 2010; 16: 1164-8.
5. -2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2009.
6. Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS,. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007; 65: 227-34. (Pubitemid 47232737)
7. Kanwal F, Gralnek IM, Hays RD, et al. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clinical Gastroenterology and Hepatology 2009; 7: 793-9.
8. Saab S, Ibrahim AB, Shpaner A, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 2005; 11: 218-23. (Pubitemid 40268220)
9. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G,. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199-205. (Pubitemid 32660918)
10. Younossi ZM, McCormick M, Price LL, et al. Impact of liver transplantation on health-related quality of life. Liver Transpl 2000; 6: 779-83.
11. Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-8. (Pubitemid 32061881)
12. Arguedas MR, DeLawrence TG, McGuire BM,. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 1622-6. (Pubitemid 36936700)
13. Campbell MS, Brensinger CM, Sanyal AJ, et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 2005; 42: 635-40. (Pubitemid 41233656)
14. Les I, Doval E, Flavia M, et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010; 22: 221-7.
15. Afendy A, Kallman JB, Stepanova M, et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 2009; 30: 469-76.
16. Kalaitzakis E, Josefsson A, Bjornsson E,. Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC gastroenterology 2008; 8: 46.
17. Kalaitzakis E, Simren M, Olsson R, et al. Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. Scand J Gastroenterol 2006; 41: 1464-72. (Pubitemid 44764408)
18. Kalaitzakis E, Bjornsson E,. Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health-related quality of life. Hepatology 2007; 46: 549-59.
19. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R,. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-59. (Pubitemid 46450607)
20. Bao ZJ, Qiu DK, Ma X, et al. Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy. World J Gastroenterol 2007; 13: 3003-8. (Pubitemid 47028892)
21. Company L, Zapater P, Perez-Mateo M, Jover R,. Extrapyramidal signs predict the development of overt hepatic encephalopathy in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 519-25.
22. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT,. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21. (Pubitemid 34183979)
23. Stewart CA, Malinchoc M, Kim WR, Kamath P,. Hepatic encephalopathy as a predictor of survival in patients with endstage liver disease. Liver Int 2009; 29: 1365-71.
24. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5. (Pubitemid 29248991)
25. Leevy CB, Phillips JA,. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007; 52: 737-41.
26. Poordad F,. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25 (s1): 3-9. (Pubitemid 46148239)
27. Bajaj JS, Hafeezullah M, Zadvornova Y, et al. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol 2009; 104: 898-905.
28. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK,. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (The RIME Trial). Am J Gastroenterol 2011; 106: 307-16.
29. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM,. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010; 31: 1012-7.
30. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D,. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300. (Pubitemid 29333782)
31. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
32. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72 (4 Pt 1): 573-83. (Pubitemid 8097592)
33. Brown RS Jr, Kumar KS, Russo MW, et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002; 8: 278-84. (Pubitemid 34257211)
34. Williams R, James OF, Warnes TW, Morgan MY,. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 203-8. (Pubitemid 30166687)
35. Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F,. Rifaximin in the treatment of hepatic encephalopathy. European Journal of Clinical Research 1993; 4: 57-66. (Pubitemid 24090546)
36. Supplement to:, Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81. Available at: http://www.nejm.org/doi/suppl/10.1056/NEJMoa0907893/suppl-file/ nejm-bass-1071sa1.pdf. Accessed July 7, 2011.
37. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis-Zouboulis I, Karamanolis DG, Ladas SD,. Long-term administration of rifaximin improves the prognosis of patients with alcohol-related deconpensated cirrhosis: a case-control study. Hepatology 2010; 52: 328A-9A.
38. Hanouneh M, Hanouneh IA, Hashash JG, et al. Rifaximin prevents spontaneous bacterial peritonitis and improves transplant free survival in patients with liver cirrhosis. Gastroenterology 2011; 140: S-903.
39. Kalambokis G, Tsianos EV,. Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count. Am J Gastroenterol 2010; 105: 2705-7.
40. Vlachogiannakos J, Saveriadis AS, Viazis N, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009; 29: 992-9.
41. Williams R,. Review article: bacterial flora and pathogenesis in hepatic encephalopathy. Alimentary Pharmacol Ther 2007; 25 (s1): 17-22. (Pubitemid 46148241)
42. Mantry PS, Munsaf S,. Rifaximin for the treatment of hepatic encephalopathy. Transplant Proc 2010; 42: 4543-7.